There is so much riding on the Mechanism of action in terms of its potential that makes Leronlimab a potential Big Pharma disruptor. But a cure here and there means a loss in revenue from those that profit from ongoing disease burden. This is why the cure for Hep C was such an unabated thing. There really was no cure or viable treatment for it. Unlike what is happening with Leronlimab.
I am becoming more convinced that FDA and BP will do to CytoDyn what GM and politicians did back then. Hate to say it, but saying odds are against leronlimab being approved, is like saying odds are against me flying to the moon. I love the science, just saying what I think.
News 
Market Data 
Discover 
